Zobrazeno 1 - 10
of 376
pro vyhledávání: '"E, Gamelin"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 1015:165770
SIRIUS (Spectroscopy & Identification of Rare Isotopes Using S3) is a detection system designed for the focal plane of S3 (the Super Separator Spectrometer), which is part of the SPIRAL2 (Systeme de Production d’Ions RAdioactifs en Ligne de 2e gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5c288fc20507b123e7a23a819784068
https://doi.org/10.1016/j.nima.2021.165770
https://doi.org/10.1016/j.nima.2021.165770
Autor:
A. Bizieux, Jean-Philippe Metges, Sophie Abadie-Lacourtoisie, Veronique Guerin-Meyer, Jean-Yves Douillard, Oana Cojocarasu, M. Kaassis, G. Ganem, O. Capitain, F. Grude, J. Baudon, C. Lafond, H. Morel, E. Blot, P. Ingrand, Fabrice Denis, M.E. Morin-Meschin, S. Corbinais, M. Marcq, L. Juhel-Voog, Valérie Delecroix, Anne-Claire Hardy-Bessard, M. Zinger, Patrick Soulié, Caroline Alleaume, Fanny Marhuenda, Y.H. Lam, R. Lamy, E. Gamelin, E. Voog, Emmanuelle Bourbouloux, Olivier Dupuis, D. Berton-Rigault, Julien Edeline, S. Lebouvier-Sadot, P. Maillart, M. Ferec, J.M. Commer, A. Gangler, B. d’Aillières, M.J. Goudier, J. Egreteau, Xavier Artignan, R. Delva, E. Naudeix, D. Déniel-Lagadec, C. Lefeuvre, C. Riché, F. Le Du, A. Zannetti, Philippe Deguiral, Hugues Bourgeois, P. Solal-Céligny
Publikováno v:
Annals of Oncology. 28:1612-1617
Background In 2008, a study of the characteristics of hospitalised patients led to the development of a prognostic tool that distinguished three populations with significantly different 2-month survival rates. The goal of our study aimed at validatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bfdb51cd99d498ae3513e78bdb12f8c
https://doi.org/10.1093/annonc/mdx172
https://doi.org/10.1093/annonc/mdx172
Autor:
J.-P. Metges, P. Laplaige, M. Campone, Alain Morel, M. Ferec, Claire Stampfli, Olivier Capitain, Thierry Lecomte, E. Gamelin, Tamara Matysiak-Budnik, Roger Faroux, Hélène Senellart, Michèle Boisdron-Celle
Publikováno v:
Annals of Oncology. 29:v60-v61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1adf8c232bc7387f2d3809a0522362a2
https://doi.org/10.1093/annonc/mdy151.215
https://doi.org/10.1093/annonc/mdy151.215
Publikováno v:
Annales de biologie clinique. 68:27-32
Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Numerous genetic mutations have been iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a41ec951eeb7b68c1423d13e9405235
https://doi.org/10.1684/abc.2010.0394
https://doi.org/10.1684/abc.2010.0394
Autor:
V. Guerin-Meyer, J.-J. Le Jeune, Sylvie Girault, Cécile Berthelot, Gérard Lorimier, Christian Jeanguillaume, P. Soulie, E. Parot-Schinkel, Olivier Morel, Gilles Metrard, E. Gamelin
Publikováno v:
Médecine Nucléaire. 33:547-552
Resume Objectifs Le but de cette etude a ete d’evaluer les performances diagnostiques et pronostiques de la TEP au 18F-FDG (TEP-FDG), ainsi que son impact sur la prise en charge therapeutique, dans l’exploration de la recidive des carcinomes colo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27f55a32b92101a3ae3db590cee208f0
https://doi.org/10.1016/j.mednuc.2009.06.003
https://doi.org/10.1016/j.mednuc.2009.06.003
Autor:
Jean-Luc Raoul, E. Francois, J.-Y. Douillard, Jaafar Bennouna, E. Gamelin, Philippe Barthélémy, Jean Francois Seitz, A. Fandi, Thierry Conroy, S. Nasca, F. Bertheault-Cvitkovic, Bernard Paillot, Yves Becouarn, M. Ychou
Publikováno v:
Annals of Oncology. 13:1072-1079
This multicenter, phase II, open-label study evaluated the antitumor efficacy and safety of oxaliplatin and raltitrexed (Tomudex) in non-pretreated advanced colorectal cancer patients.Seventy-one patients received oxaliplatin 130 mg/m(2) and raltitre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f540086dce5b0244b2bf2e362bf2541b
https://doi.org/10.1093/annonc/mdf183
https://doi.org/10.1093/annonc/mdf183
Autor:
Ph. Chollet, Véronique Diéras, E. Gamelin, M. Spielmann, Laurent Zelek, Michel Marty, J.-M. Vannetzel, J.L. Misset, S. Mackenzie, N. Chouaki, Michèle Tubiana-Hulin, Stéphane Culine, Paul-Henri Cottu
Publikováno v:
Journal of Clinical Oncology. 20:2551-2558
PURPOSE: Phase II study evaluating efficacy and safety of combined oxaliplatin/fluorouracil (5-FU) in taxane-pretreated advanced and metastatic breast cancer (ABC) patients. PATIENTS AND METHODS: Sixty-four taxane- and anthracycline-pretreated (withi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2825ca01116171316eb5f1d279e5959a
https://doi.org/10.1200/jco.2002.06.164
https://doi.org/10.1200/jco.2002.06.164
Publikováno v:
Les biomarqueurs moléculaires en oncologie ISBN: 9782817804446
Malgre les observations, du debut du siecle precedent, montrant une liaison des effets secondaires de medicaments a des variations metaboliques interindividuelles transmissibles, la pharmacogenetique n’a ete identifiee officiellement comme une disc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::230b59c00209bce8d19250a07d879805
https://doi.org/10.1007/978-2-8178-0445-3_7
https://doi.org/10.1007/978-2-8178-0445-3_7
Autor:
P.-H. Laplaige, J. Otero, A. Laadem, M. Fabro, J. L. Frobert, D. Langlois, Ph. Chollet, Ph-H. Vennin, E. Gamelin, Pierre Pouillart, V. Lucas, Enrico Cortesi, D. Castera, J.L. Misset
Publikováno v:
Annals of Oncology. 12:1411-1415
Summary Purpose A phase II–III randomised study to compare safety and efficacy of an oxaliplatin/cyclophosphamide (OXAC) combination, vs. the reference combination of cisplatin/cyclophosphamide (CPC), in untreated advanced ovarian cancer patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b7dd445b76fc97e91317ceeb5d7c794
https://doi.org/10.1023/a:1012556627852
https://doi.org/10.1023/a:1012556627852